300016 北陆药业
已收盘 02-06 15:00:00
资讯
新帖
简况
北陆药业最新公告：2025年净利同比预增537.28%-852.26%
证券之星 · 01-29
北陆药业最新公告：2025年净利同比预增537.28%-852.26%
北陆药业（300016）披露全资子公司取得香港中成药注册证明书公告，1月23日股价上涨2.82%
证券之星 · 01-23
北陆药业（300016）披露全资子公司取得香港中成药注册证明书公告，1月23日股价上涨2.82%
股市必读：北陆药业（300016）1月16日董秘有最新回复
证券之星 · 01-19
股市必读：北陆药业（300016）1月16日董秘有最新回复
北陆药业：持有医未医疗14.99%股份
证券之星 · 01-16
北陆药业：持有医未医疗14.99%股份
股市必读：北陆药业（300016）1月12日董秘有最新回复
证券之星 · 01-13
股市必读：北陆药业（300016）1月12日董秘有最新回复
北陆药业：出口收入结构中原料药比重较高
证券之星 · 01-12
北陆药业：出口收入结构中原料药比重较高
北陆药业：持有医未医疗14.9881%股份
证券之星 · 01-12
北陆药业：持有医未医疗14.9881%股份
北陆药业（300016）披露召开2026年第一次临时股东会提示性公告，1月7日股价下跌3.6%
证券之星 · 01-07
北陆药业（300016）披露召开2026年第一次临时股东会提示性公告，1月7日股价下跌3.6%
股市必读：北陆药业（300016）12月26日董秘有最新回复
证券之星 · 2025-12-29
股市必读：北陆药业（300016）12月26日董秘有最新回复
北陆药业：取得枸橼酸西地那非口崩片注册证书
证券之星 · 2025-12-26
北陆药业：取得枸橼酸西地那非口崩片注册证书
北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》
智通财经 · 2025-12-25
北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》
北陆药业拟募资1.59亿元投建亳州化药生产基地与智能仓库项目
中金财经 · 2025-12-24
北陆药业拟募资1.59亿元投建亳州化药生产基地与智能仓库项目
北陆药业（300016）披露2025年度以简易程序向特定对象发行股票预案（修订稿），12月23日股价下跌0.25%
证券之星 · 2025-12-23
北陆药业（300016）披露2025年度以简易程序向特定对象发行股票预案（修订稿），12月23日股价下跌0.25%
北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书
智通财经 · 2025-12-12
北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书
北陆药业：截至2025年9月末公司股东总户数为42,945户
证券之星 · 2025-12-03
北陆药业：截至2025年9月末公司股东总户数为42,945户
北陆药业：九味镇心颗粒是公司独家品种
证券之星 · 2025-11-13
北陆药业：九味镇心颗粒是公司独家品种
北陆药业：钆布醇注射剂中选第十一批集采
证券之星 · 2025-11-13
北陆药业：钆布醇注射剂中选第十一批集采
北陆药业（300016）披露为全资子公司提供担保议案，11月12日股价上涨2.96%
证券之星 · 2025-11-12
北陆药业（300016）披露为全资子公司提供担保议案，11月12日股价上涨2.96%
北陆药业(300016.SZ)获得碘美普尔注射液药品注册证书
智通财经 · 2025-11-10
北陆药业(300016.SZ)获得碘美普尔注射液药品注册证书
北陆药业最新公告：钆布醇注射剂拟中选第十一批全国药品集中采购
证券之星 · 2025-10-29
北陆药业最新公告：钆布醇注射剂拟中选第十一批全国药品集中采购
加载更多
公司概况
公司名称：
北京北陆药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-10-30
主营业务：
北京北陆药业股份有限公司的主营业务是对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品是化学仿制药、中成药、原料药。
发行价格：
17.86
{"stockData":{"symbol":"300016","market":"SZ","secType":"STK","nameCN":"北陆药业","latestPrice":9.91,"timestamp":1770361407000,"preClose":10.24,"halted":0,"volume":56064456,"delay":0,"changeRate":-0.0322,"floatShares":562000000,"shares":563000000,"eps":0.0594,"marketStatus":"已收盘","change":-0.33,"latestTime":"02-06 15:00:00","open":10.31,"high":10.78,"low":9.9,"amount":570000000,"amplitude":0.0859,"askPrice":9.92,"askSize":1356,"bidPrice":9.91,"bidSize":1126,"shortable":0,"etf":0,"ttmEps":0.0594,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":10.24,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":11.26,"lowLimit":9.22,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":562873163,"isCdr":false,"pbRate":2.61,"roa":"--","peRate":166.835017,"roe":"2.46%","epsLYR":0.03,"committee":0.484463,"marketValue":5578000000,"turnoverRate":0.0997,"status":1,"floatMarketCap":5571000000},"requestUrl":"/m/hq/s/300016","defaultTab":"news","newsList":[{"id":"2607024088","title":"北陆药业最新公告：2025年净利同比预增537.28%-852.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607024088","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607024088?lang=zh_cn&edition=full","pubTime":"2026-01-29 18:29","pubTimestamp":1769682584,"startTime":"0","endTime":"0","summary":"北陆药业(300016.SZ)公告称，预计2025年归属于上市公司股东的净利润为8700万元–13000万元，比上年同期增长537.28%–852.26%。业绩变动原因：公司坚持“化药+中成药”双轮驱动战略，深耕国内外市场，推动各板块收入持续增长；深化降本增效，提升运营效能；“北陆转债”赎回致财务费用显著下降，叠加参股企业股权公允价值上升，共同推动净利润大幅增长。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900032709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300016","BK0042","BK0046","BK0060"],"gpt_icon":0},{"id":"2605406789","title":"北陆药业（300016）披露全资子公司取得香港中成药注册证明书公告，1月23日股价上涨2.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605406789","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605406789?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:52","pubTimestamp":1769179937,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，北陆药业报收于9.48元，较前一交易日上涨2.82%，最新总市值为53.36亿元。该股当日开盘9.23元，最高9.57元，最低9.23元，成交额达2.12亿元，换手率为3.98%。北陆药业于2026年1月23日发布《关于全资子公司取得香港中成药注册证明书的公告》。该产品已获准在香港出售，中成药注册编号为HKC-18750，有效期至2031年1月12日。此举标志着公司核心中成药九味镇心颗粒获得香港市场准入资格，有助于拓展海外市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300016","BK0042","BK0060"],"gpt_icon":0},{"id":"2604979439","title":"股市必读：北陆药业（300016）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604979439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604979439?lang=zh_cn&edition=full","pubTime":"2026-01-19 00:58","pubTimestamp":1768755490,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，北陆药业报收于9.21元，下跌4.56%，换手率7.0%，成交量39.32万手，成交额3.68亿元。董秘最新回复投资者： 领导好！目前公司持有医未医疗14.99%的股份，持有世和基因16.38%的股份，持有芝友医疗24.25%的股份，均为这三家公司第二大股东。当日关注点来自交易信息汇总：1月16日主力资金净流出7416.08万元，散户资金净流入7814.89万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900000334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0042","BK0060","BK0239"],"gpt_icon":0},{"id":"2603896834","title":"北陆药业：持有医未医疗14.99%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603896834","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603896834?lang=zh_cn&edition=full","pubTime":"2026-01-16 15:33","pubTimestamp":1768548791,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业01月16日在投资者关系平台上答复投资者关心的问题。近日，公众号《陆玉龙卓越企业研究》发文《北陆药业 2025上涨29.11%，2026如何？》预测说，2026年“三参两控”企业总体发展将有重大突破，可能为北陆药业贡献净利润。目前公司持有医未医疗14.99%的股份，持有世和基因16.38%的股份，持有芝友医疗24.25%的股份，均为这三家公司第二大股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600019271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0060","BK0239","300016","159891"],"gpt_icon":0},{"id":"2603400045","title":"股市必读：北陆药业（300016）1月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603400045?lang=zh_cn&edition=full","pubTime":"2026-01-13 02:20","pubTimestamp":1768242020,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，北陆药业报收于9.44元，上涨2.39%，换手率8.34%，成交量46.91万手，成交额4.39亿元。目前公司出口收入结构中原料药比重较高，故出口业务整体毛利率与原料药及其他毛利率相对接近。目前公司持有医未医疗14.9881%的股份，系其第二大股东。当日关注点来自交易信息汇总：1月12日主力资金净流入725.04万元，显示主力对北陆药业的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300001688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0060","BK0239","BK0042"],"gpt_icon":0},{"id":"2602597620","title":"北陆药业：出口收入结构中原料药比重较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2602597620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602597620?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:42","pubTimestamp":1768207329,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业01月12日在投资者关系平台上答复投资者关心的问题。营收上确实大幅增长，但2024年度境外业务的整体毛利率仅为17.57%，大幅低于披露的对比剂毛利率49.2%，与“原料药及其他”17.01%的毛利率相近，主要原因是什么？目前公司出口收入结构中原料药比重较高，故出口业务整体毛利率与原料药及其他毛利率相对接近。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200020863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0042","300016","BK0060"],"gpt_icon":0},{"id":"2602597603","title":"北陆药业：持有医未医疗14.9881%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2602597603","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602597603?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:39","pubTimestamp":1768207153,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：医未医疗是国内唯一覆盖脑部疾病“筛查-诊断-康复”全流程的脑科学AI企业，技术路径为非侵入式脑机接口+神经调控+医疗AI，聚焦卒中、AD、认知障碍等刚需场景。请问贵公司目前持有医未医疗多少股份？医未医疗是否考虑IPO？谢谢北陆药业回复：感谢您的关注。目前公司持有医未医疗14.9881%的股份，系其第二大股东。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200020524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","159891","BK0042","BK0239","BK0046","300016"],"gpt_icon":0},{"id":"2601809661","title":"北陆药业（300016）披露召开2026年第一次临时股东会提示性公告，1月7日股价下跌3.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809661","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601809661?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:12","pubTimestamp":1767795137,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，北陆药业报收于8.83元，较前一交易日下跌3.6%，最新总市值为49.7亿元。该股当日开盘9.1元，最高9.11元，最低8.8元，成交额达3.22亿元，换手率为6.42%。公司近日发布公告称，将于2026年1月8日召开2026年第一次临时股东会，会议由董事会召集，现场会议时间为当日14:30，网络投票时间为当日9:15至15:00。股权登记日为2025年12月31日。上述议案均为特别决议事项，需经出席会议股东所持表决权的三分之二以上通过。中小投资者表决将单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700038718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0042","BK0239","BK0060"],"gpt_icon":0},{"id":"2595503279","title":"股市必读：北陆药业（300016）12月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595503279","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595503279?lang=zh_cn&edition=full","pubTime":"2025-12-29 04:25","pubTimestamp":1766953511,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，北陆药业报收于8.09元，下跌0.12%，换手率1.64%，成交量9.22万手，成交额7556.41万元。董秘最新回复投资者： 请问贵司取得的枸橼酸西地那非的药，这个药的利润率是否高于公司目前其他产品的平均利润率?公司于近期取得枸橼酸西地那非口崩片的《药品注册证书》，目前正积极开展新产品上市的各项准备工作，并尽快将产品推向市场。当日关注点来自交易信息汇总：12月26日主力资金净流出69.0万元，散户资金净流入203.05万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900001646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2594490267","title":"北陆药业：取得枸橼酸西地那非口崩片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594490267","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594490267?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:54","pubTimestamp":1766739247,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)12月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司取得的枸橼酸西地那非的药，这个药的利润率是否高于公司目前其他产品的平均利润率? 这款药品将给公司明年带来多大的业绩提升?北陆药业回复：感谢您的关注。公司于近期取得枸橼酸西地那非口崩片的《药品注册证书》，目前正积极开展新产品上市的各项准备工作，并尽快将产品推向市场。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600023372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0042","BK0239","BK0060"],"gpt_icon":0},{"id":"2594238146","title":"北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2594238146","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594238146?lang=zh_cn&edition=full","pubTime":"2025-12-25 15:53","pubTimestamp":1766649199,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的枸橼酸西地那非口崩片的《药品注册证书》。西地那非为5型磷酸二酯酶选择性抑制剂，用于治疗勃起功能障碍，具有起效迅速、疗效确切等优势。枸橼酸西地那非口崩片为美国辉瑞公司开发的西地那非迭代剂型，2019年在中国批准进口。枸橼酸西地那非口崩片无需患者饮水、口腔放置数秒即可崩解、起效时间快，可满足该类患者对于服用方便、起效快、隐私性好的口服药物的需求，为患者提供更灵活多样的用药选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0046","300016","BK0042","BK0060"],"gpt_icon":0},{"id":"2593044159","title":"北陆药业拟募资1.59亿元投建亳州化药生产基地与智能仓库项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2593044159","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593044159?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:06","pubTimestamp":1766534773,"startTime":"0","endTime":"0","summary":"中访网数据 北京北陆药业股份有限公司近日发布公告，计划以简易程序向特定对象发行股票，募集资金总额不超过1.59亿元，扣除发行费用后全部用于其全资子公司陆芝葆药业有限公司在安徽省亳州市谯城区实施的“陆芝葆化药生产车间与智能综合仓库项目”。该项目总投资额约为3.93亿元，旨在扩大公司在高端化学仿制药领域的产能并建设现代化智能仓储体系。化药生产车间建设周期预计为36个月，智能仓库建设周期为12个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251224/31886132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0060","BK0042","BK0239","BK0046","300016"],"gpt_icon":0},{"id":"2593928416","title":"北陆药业（300016）披露2025年度以简易程序向特定对象发行股票预案（修订稿），12月23日股价下跌0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593928416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593928416?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:46","pubTimestamp":1766501197,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，北陆药业报收于8.06元，较前一交易日下跌0.25%，最新总市值为45.37亿元。该股当日开盘8.11元，最高8.11元，最低7.98元，成交额达4399.36万元，换手率为0.97%。近日，北京北陆药业股份有限公司发布《2025年度以简易程序向特定对象发行股票预案（修订稿）》。公告显示，公司拟以简易程序向特定对象发行股票，募集资金总额不超过15,900.00万元，用于陆芝葆化药生产车间与智能综合仓库项目。本次发行不会导致公司控制权变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300041144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300016","BK0046","BK0060","BK0239"],"gpt_icon":0},{"id":"2590866576","title":"北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590866576","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590866576?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:46","pubTimestamp":1765525578,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)公告，公司收到国家药品监督管理局核准签发的吡格列酮二甲双胍片(15mg/500mg)的《药品注册证书》。本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300016","BK0046","BK0042","BK0239"],"gpt_icon":0},{"id":"2588701165","title":"北陆药业：截至2025年9月末公司股东总户数为42,945户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701165?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:03","pubTimestamp":1764752590,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到2025年11月30日，公司股东人数是多少？北陆药业回复：感谢您的关注。截至2025年9月末公司股东总户数为42,945户，截至2025年12月末的公司股东总户数将在《2025年年度报告》中披露，敬请关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2583559094","title":"北陆药业：九味镇心颗粒是公司独家品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559094","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583559094?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019948,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问九味镇心颗粒是否为北陆药业独家品种？北陆药业回复：感谢您的关注。九味镇心颗粒是公司自主研发的中药创新药，是国家食品药品监督管理总局批准治疗广泛性焦虑症的纯中药制剂，医保品种，也是公司的独家品种。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","300016","BK0239","BK0042"],"gpt_icon":0},{"id":"2583559055","title":"北陆药业：钆布醇注射剂中选第十一批集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583559055?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019936,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业11月13日在投资者关系平台上答复投资者关心的问题。我想查询贵公司在国家组织药品集中采购中的中选药品的销售额这一数据，在哪里可以获取呢？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0060","BK0239","BK0042"],"gpt_icon":0},{"id":"2582377377","title":"北陆药业（300016）披露为全资子公司提供担保议案，11月12日股价上涨2.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377377","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377377?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:14","pubTimestamp":1762956866,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，北陆药业报收于9.05元，较前一交易日上涨2.96%，最新总市值为50.94亿元。该股当日开盘8.76元，最高9.07元，最低8.73元，成交额达3.22亿元，换手率为6.38%。公司近日发布公告称，将于2025年11月13日召开2025年第四次临时股东会，会议由董事会召集，现场会议时间为当日14:30，网络投票时间为当日9:15至15:00。本次股东会将审议关于为全资子公司陆芝葆药业有限公司提供担保的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0046","300016","BK0239","BK0042"],"gpt_icon":0},{"id":"2582231498","title":"北陆药业(300016.SZ)获得碘美普尔注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582231498","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582231498?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:22","pubTimestamp":1762762978,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 北陆药业 发布公告，近日，公司收到国家药品监督管理局核准签发的碘美普尔注射液《药品注册证书》。碘美普尔注射液由意大利Bracco研制，属于一种非离子型单体X射线造影剂。碘美普尔注射液已纳入国家医保乙类目录。根据米内网数据显示，近年来在中国三大终端六大市场的销售额均以两位数的增速增长，2024年超过11亿元，同比增长约32%;2025年一季度超过3亿元，同比增长约39%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0042","BK0060","300016","BK0239"],"gpt_icon":0},{"id":"2579549973","title":"北陆药业最新公告：钆布醇注射剂拟中选第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2579549973","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579549973?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:47","pubTimestamp":1761731257,"startTime":"0","endTime":"0","summary":"北陆药业公告称，公司钆布醇注射剂拟中选第十一批全国药品集中采购。该产品于2022年4月和2024年4月分别获得国家药品监督管理局核准签发的《药品注册证书》及《药品补充申请批准通知书》。随着中选结果的执行，钆布醇注射剂有望快速打开市场，提升公司对比剂产品的市场份额和品牌影响力。但采购合同签订等后续事项以及带量采购后市场销售执行情况存在不确定性，公司将密切关注进展并及时披露信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900037427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300016","BK0046","BK0042","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770593454389,"stockEarnings":[{"period":"1week","weight":0.0123},{"period":"1month","weight":0.1223},{"period":"3month","weight":0.1577},{"period":"6month","weight":0.0269},{"period":"1year","weight":0.5871},{"period":"ytd","weight":0.2481}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京北陆药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42945人(较上一季度减少2.23%)","perCapita":"13089股","listingDate":"2009-10-30","address":"北京市密云区水源西路3号","registeredCapital":"56287万元","survey":" 北京北陆药业股份有限公司的主营业务是对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品是化学仿制药、中成药、原料药。","listedPrice":17.86},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北陆药业,300016,北陆药业股票,北陆药业股票老虎,北陆药业股票老虎国际,北陆药业行情,北陆药业股票行情,北陆药业股价,北陆药业股市,北陆药业股票价格,北陆药业股票交易,北陆药业股票购买,北陆药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}